Regdanvimab lowered hospitalisation, oxygen need or death risk by 70% in Covid-19 patients versus placebo in Phase III trial. Credit: Dim Hou / Unsplash.

Health Canada has granted priority review to Celltrion Healthcare’s experimental monoclonal antibody, regdanvimab (CT-P59), for the treatment of Covid-19.

In May, Celltrion filed new drug submission (NDS) to the agency. The company noted that the screening phase was complete and the application has been accepted for review.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The rolling submission process aids the company to submit safety and efficacy data and information when they become available.

In addition, it permits Health Canada to commence the review process immediately, as data is made available continuously, to expedite the overall review process.

Celltrion Healthcare Canada commercial director Jovan Antunovic said: “We are pleased the new drug submission has been screened and accepted for review by Health Canada and anticipate this accelerated review process will enable people in Canada to have access to safe and effective treatment against Covid-19 as early as possible.

“The initiation of a rolling submission for regdanvimab (CT-P59) in Canada is a significant milestone and we remain committed to closely working with the Canadian regulatory authorities.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to data from pre-clinical studies, the antibody demonstrated the ability to attach to SARS-CoV-2’s receptor-binding domain (RBD) and substantially neutralise the wild type virus.

In an international Phase III trial, regdanvimab lowered the risk of Covid-19 linked hospitalisation, oxygen treatment or death by 72% in patients who were at increased risk of disease progression.

The drug reduced the risk by 70% in all treated participants versus placebo.

Furthermore, regdanvimab treatment offered a minimum of 4.7 days and 4.9 days decrease in time to clinical recovery in patients at increased risk of disease progression and overall patient population, respectively, versus placebo.

In March, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that regdanvimab can be used for the treatment of patients who are at increased risk of progressing to severe Covid-19.

At present, Celltrion is developing a neutralising antibody cocktail with regdanvimab for several SARS-CoV-2’s emergent variants.